The genetic basis of cancer is increasingly understood, driving significant advances in personalized medicine.  Next-generation sequencing technologies have revolutionized our ability to identify somatic mutations driving tumorigenesis, enabling the precise characterization of individual cancers. This detailed genomic profiling reveals specific driver mutations, fusion genes, and copy number variations, paving the way for targeted therapies.  Recent breakthroughs include the development of highly specific inhibitors targeting oncogenic kinase mutations, such as those found in EGFR-mutated lung cancers or BRAF-mutated melanomas, demonstrating the efficacy of precision oncology. Furthermore, immunotherapies, harnessing the power of the patient's own immune system, are increasingly personalized based on the tumor's mutational burden and expression of immune checkpoints.  Advances in liquid biopsies, analyzing circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), offer minimally invasive methods for continuous monitoring of disease progression, treatment response, and the emergence of resistance mutations, allowing for timely therapeutic adjustments.  However, challenges remain, including the complexity of tumor heterogeneity, the identification of actionable mutations, and the high cost of comprehensive genomic profiling, necessitating ongoing research and development to fully realize the potential of personalized cancer medicine.